Some Incurable BRCA Patients Respond to New 2-Drug Combo, Dana-Farber Cancer Institute Study

A novel combination of two drugs has shown anti-cancer activity in patients who had incurable solid tumors and carried a germline mutation in their BRCA genes, Dana-Farber Cancer Institute researchers are reporting at the American Association for Cancer Research annual meeting in Washington, April 6-10.

Back to news